阅读说明：本技术 具有抗微生物活性的挥发性有机化合物制剂 (Volatile organic compound formulations with antimicrobial activity ) 是由 G·A·斯通博 B·布拉特 于 2019-09-27 设计创作，主要内容包括：本主题包括在治疗或预防感染以及处理可能被感染物污染的各种表面的广泛应用中具有抗微生物、抗真菌、抗菌和相关作用的新型化学制剂。在一些实施方案中,所述制剂还包含己酸异戊酯与丙酸和/或异丁酸中的至少一种。(The present subject matter includes novel chemical formulations having antimicrobial, antifungal, antibacterial and related effects in a wide range of applications for treating or preventing infections and treating various surfaces that may be contaminated with infectious agents. In some embodiments, the formulation further comprises isoamyl hexanoates and at least one of propionic acid and/or isobutyric acid.)

1. An agent having antimicrobial, antifungal, antibacterial, antiprotozoal or antiparasitic action comprising isoamyl hexanoates with at least one acid selected from propionic acid and isobutyric acid.

2. The formulation of claim 1, wherein the formulation is in the form of a cream, ointment, lotion, oil, scrub, spray, shampoo, gel, plaster, solution, suspension, infusion, salve, ear wash, powder, eye wash, mouthwash, nail polish, or gas.

3. The formulation of claim 2, wherein the formulation is in the form of a mouthwash.

4. The formulation of claim 1, wherein the formulation is in a form suitable for treating a wound to treat or prevent infection.

5. The formulation of claim 4, wherein the formulation is in the form of a cream or ointment.

6. The formulation of claim 1, wherein the formulation is in the form of a nail polish or a skin treatment agent.

7. The formulation of claim 1, wherein the formulation is in a form suitable for treating human or animal feces.

8. The preparation of claim 1, wherein the preparation is in a form suitable for inclusion in an animal feed or feed supplement.

9. A method of treating or preventing pathogenic or wound infections comprising administering to a subject or surface in need thereof an effective amount of the formulation of claim 1.

10. A method of treating or preventing pathogenic or wound infections comprising administering to a subject or surface in need thereof an effective amount of the formulation of claim 2.

11. A method of treating or preventing an oral infection comprising administering to a subject in need thereof an effective amount of the formulation of claim 3.

12. A method of treating or preventing an infection during or after a medical procedure comprising administering an effective amount of the formulation of claim 2 at an appropriate time before, during and/or after the medical procedure.

13. A method of treating or preventing a fungal infection comprising administering to a subject in need of such treatment or prevention an effective amount of the formulation of claim 1.

14. The method of claim 12, wherein the formulation is administered to the subject's nail bed or skin.

15. The method of claim 13, wherein the formulation is administered to treat or prevent a fungal infection of the uterus.

16. A method of applying the formulation of claim 7 to litter or feces in a hospital or home.

17. A method of maintaining or improving the health of an animal comprising administering an effective amount of the formulation of claim 8.

18. The method of claim 17, wherein the administering comprises periodic or cyclical administration of the formulation of claim 8.

19. A method of disinfecting a surface comprising applying to the surface an effective amount of the formulation of claim 1.

20. The method of claim 19, wherein the surface is located at a home, hospital, or food processing center or location.

Background

The importance of safely disposing of billions of pounds of human and animal waste daily to avoid the myriad of health problems associated with such waste is not exaggerated. In fact, only a small portion of this mass of material is safely disposed of, while the remaining portion is untreated and poses a threat to human and animal health. For example, it is well known that a complex of bacterial and other agents responsible for gastrointestinal disease is the single largest cause of death worldwide. It is also well known that these types of diseases primarily affect infants and children, as well as livestock. It is estimated that in the next decade, at least two million people will die of poor or inadequate sanitation facilities.

One reason for this is that about 24 million people live in areas where there are insufficient sanitary facilities. Nearly 4000 children die each day from conditions such as diarrhea. Furthermore, people suffering from water-borne diseases account for about half of hospital beds worldwide. In several asian countries, up to two times of people die from diarrhea-related diseases, such as AIDS. Poor hygienic conditions are essentially caused by or associated with the inability to adequately treat and dispose of human and animal faeces, which carry pathogenic microorganisms and promote their growth and development, at home, socially and in some cases even throughout the country.

The deleterious effects of microorganisms in industrial environments are, of course, numerous. For example, safer and more effective means for treating microorganism-laden surfaces in medical or hospital environments are needed. There is a need for safer and more effective means for treating crops for growth of harmful microorganisms. Further, means for reducing the unpleasant odor generated by the decomposition of fecal matter in industrial farming operations are highly desirable.

There is an urgent need to replace antibiotics with other types of compounds that also exhibit antimicrobial activity. The long-lasting use of most commonly used antibiotics for animals and agriculture has resulted in acquired resistance of microbial populations, particularly microorganisms capable of causing disease. Every year, at least 23,000 people die in the united states due to infections caused by drug-resistant bacteria, and the number is increasing.

Accordingly, there is a need in the art for antimicrobial compositions, and formulations and methods for human and animal fecal management, that are suitable for reducing the effects of microorganisms and microbial growth in a wide range of industrial environments. The present invention meets this need.

Summary of The Invention

In one embodiment, the present invention relates to a chemical formulation having antimicrobial activity comprising propanoic acid, isobutryic acid and at least one ester. In another embodiment, the at least one ester is isoamyl hexanoates. In another embodiment, the formulation further comprises at least one carrier selected from the group consisting of bentonite, zeolite, and perlite. In another embodiment, the ratio of propanoic acid to isobutyric acid to isoamyl hexanoates is about 3.5:3.5:2 (v/v/v). In another embodiment, the ratio of propanoic acid, isobutyric acid, and isoamyl hexanoates is about 7 parts of the two acids and 2 parts of isoamyl butyrate. In another embodiment, the formulation further comprises at least one endophyte (endophyte). In another embodiment, the endophyte is from fusarium.

In another embodiment, the invention relates to a chemical formulation consisting essentially of propanoic acid, isobutryic acid, isoamyl hexanoates and a carrier selected from the group consisting of bentonite, zeolite and perlite.

In another embodiment, the present invention relates to a chemical formulation comprising propionic acid and at least one 6-12 carbon (acid) component ester, wherein the ratio of propionic acid to ester component of the chemical formulation is about 7:2 (v/v). In another embodiment, the at least one ester is isoamyl hexanoates. In another embodiment, the formulation further comprises at least one nutritional supplement and at least one salt. In another embodiment, the formulation comprises glucose, whey protein, potassium chloride, magnesium sulfate, and sodium chloride. In another embodiment, the formulation comprises glucose, glycine, potassium chloride, sodium chloride, and magnesium acetate. In another embodiment, the formulation comprises glucose, glycine, potassium chloride, sodium chloride, magnesium acetate, and potassium dihydrogen phosphate. In another embodiment, the formulation further comprises at least one carrier. In another embodiment, the formulation consists essentially of propionic acid and isoamyl hexanoates in a ratio of propionic acid to isoamyl hexanoates of about 7:2 (v/v). In another embodiment, the formulation comprises at least one probiotic. In another embodiment, the endophyte is from fusarium.

In another embodiment, the invention relates to a method of treating an animal having a disease or condition associated with a microbial infection comprising administering to the animal an effective amount of a composition comprising at least one organic acid and at least one ester. In another embodiment, the invention relates to a composition comprising propionic acid and at least one 6-12 carbon (acid) component ester, wherein the ratio of propionic acid to ester component of the chemical is about 7:2 (v/v).